Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Maschmeyer, G' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 50 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Maschmeyer, G
      Pneumonia in febrile neutropenic patients: radiologic diagnosis

      CURRENT OPINION IN ONCOLOGY
    2. Buchner, T; Hiddemann, W; Berdel, W; Wormann, B; Loffler, H; Schoch, C; Haferlach, T; Ludwig, WD; Maschmeyer, G; Staib, P; Andreesen, R; Balleisen, L; Haase, D; Eimermacher, H; Aul, C; Rasche, H; Uhlig, J; Gruneisen, A; Reis, HE; Hartlapp, J; Hirschmann, WD; Weh, HJ; Pielken, HJ; Gassmann, W; Sauerland, MC; Heinecke, A
      Remission induction therapy: the more intensive the better?

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    3. Reich, G; Mapara, MY; Reichardt, P; Dorken, B; Maschmeyer, G
      Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiplemyeloma and patients with solid tumors

      BONE MARROW TRANSPLANTATION
    4. Reich, G; Held, T; Siegert, W; Kampf, D; Dorken, B; Maschmeyer, G
      Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation

      BONE MARROW TRANSPLANTATION
    5. Einsele, H; Bertz, H; Beyer, J; Kiehl, MG; Runde, V; Kolb, HJ; Holler, E; Beck, R; Schwerdfeger, R; Schumacher, U; Hebart, H; Martin, H; Kienast, J; Ullmann, AJ; Maschmeyer, G; Kruger, W; Link, H; Schmidt, CA; Oettle, H; Klingebiel, T
      Reports of society meetings and consensus conferences

      DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
    6. Wilhelm, M; Hiddemann, W; Maschmeyer, G; Link, H; Buchheidt, D; Glass, B; Cornely, O; Helmerking, M; Adam, D
      Empirical antimicrobial therapy of FUO and proved infections in neutropenic patients

      ACUTE LEUKEMIAS VIII: PROGNOSTIC FACTORS AND TREATMENT STRATEGIES
    7. Maschmeyer, G; Braveny, I
      Review of the incidence and prognosis of Pseudomonas aeruginosa infectionsin cancer patients in the 1990s

      EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
    8. Buchner, T; Hiddemann, W; Wormann, B; Loffler, H; Ludwig, WD; Schoch, C; Haferlach, T; Maschmeyer, G; Staib, P; Aul, C; Heyll, A; Gruneisen, A; Rasche, H; Eimermacher, H; Balleisen, L; Pielken, HJ; Reis, HE; Griesinger, F; Reichle, A; Sauerland, MC; Heinecke, A
      Acute myeloid leukemia in adults: Is postconsolidation maintenance therapynecessary?

      INTERNATIONAL JOURNAL OF HEMATOLOGY
    9. Gokbuget, N; Hoelzer, D; Arnold, R; Bohme, A; Bartram, CR; Freund, M; Ganser, A; Kneba, M; Langer, W; Lipp, T; Ludwig, WD; Maschmeyer, G; Rieder, H; Thiel, E; Weiss, A; Messerer, D
      Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL)

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    10. Buchheidt, D; Hiddemann, W; Krcmery, V; Karthaus, M; Donnelly, JP; Wilhelm, M; Maschmeyer, G; Link, H; Adam, D; Helmerking, M
      European surveillance of infections and risk factors in cancer patients

      EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
    11. Reinhardt, P; Maschmeyer, G; Schulze, G; Fleischer, C; Ellerbrok, H; Schlegelberger, B; Stein, H; Pauli, G; Ludwig, WD
      First non-imported HTLV-1 positive adult T cell leukemia/lymphoma (ATLL) in Germany

      LEUKEMIA
    12. Maschmeyer, G
      Interventional antimicrobial therapy in febrile neutropenic patients

      DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
    13. Buchner, T; Wormann, B; Loffler, H; Gassmann, W; Haferlach, T; Fonatsch, C; Haase, D; Schoch, C; Hossfeld, D; Lengfelder, E; Aul, C; Heyll, A; Maschmeyer, G; Ludwig, WD; Sauerland, MC; Heinecke, A
      Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group

      BLOOD
    14. KERN W; AUL C; MASCHMEYER G; KUSE R; KERKHOFF A; GROTEMETKE A; EIMERMACHER H; KUBICA U; WORMANN B; BUCHNER T; HIDDEMANN W
      GRANULOCYTE-COLONY-STIMULATING FACTOR SHORTENS DURATION OF CRITICAL NEUTROPENIA AND PROLONGS DISEASE-FREE SURVIVAL AFTER SEQUENTIAL HIGH-DOSE CYTOSINE-ARABINOSIDE AND MITOXANTRONE (S-HAM) SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE MYELOID-LEUKEMIA

      Annals of hematology
    15. BEHRE G; LINK H; MASCHMEYER G; MEYER P; PAAZ U; WILHELM M; HIDDEMANN W
      MEROPENEM MONOTHERAPY VERSUS COMBINATION THERAPY WITH CEFTAZIDIME ANDAMIKACIN FOR EMPIRICAL-TREATMENT OF FEBRILE NEUTROPENIC PATIENTS

      Annals of hematology
    16. KERN W; AUL C; MASCHMEYER G; SCHONROCKNABULSI R; LUDWIG WD; BARTHOLOMAUS A; BETTELHEIM P; WORMANN B; BUCHNER T; HIDDEMANN W
      SUPERIORITY OF HIGH-DOSE OVER INTERMEDIATE-DOSE CYTOSINE-ARABINOSIDE IN THE TREATMENT OF PATIENTS WITH HIGH-RISK ACUTE MYELOID-LEUKEMIA - RESULTS OF AN AGE-ADJUSTED PROSPECTIVE RANDOMIZED COMPARISON

      Leukemia
    17. FREUND M; HEIL G; ARNOLD R; BALLEISEN L; BUCHNER T; DIEDRICH H; EIMERMACHER H; FONATSCH C; GANSER A; GASSMANN W; HARTMANN F; HIDDEMANN W; KASPER C; KNAUF WU; KOCH P; KUBICA U; LINK H; LOFFLER H; LUDWIG WD; MASCHMEYER G; POMPE K; SCHADECK C; SCHMITZ N; SCHONROCKNABULSI P; SCHWONZEN M; THIEL E; WEISS A; HOELZER D
      THE ROLE OF BONE-MARROW TRANSPLANTATION AND HIGH-DOSE CHEMOTHERAPY INRELAPSING ACUTE LYMPHOCYTIC-LEUKEMIA

      Bone marrow transplantation
    18. MASCHMEYER G
      ANTIBIOTIC-TREATMENT IN NEUTROPENIA - REP LY

      Deutsche Medizinische Wochenschrift
    19. MASCHMEYER G; HIDDEMANN W; LINK H; CORNELY OA; BUCHHEIDT D; GLASS B; ADAM D
      MANAGEMENT OF INFECTIONS DURING INTENSIVE TREATMENT OF HEMATOLOGIC MALIGNANCIES

      Annals of hematology
    20. HIDDEMANN W; MASCHMEYER G; LINK H; HELMERKING M; ADAM D
      TREATMENT OF INFECTIONS IN ACUTE LEUKEMIA S

      Medizinische Klinik
    21. WORMANN B; SAUERLAND C; HEINECKE A; LOFFLER H; GASSMANN W; HAFERLACH T; HOSSFELD D; LENGFELDER E; LUDWIG WD; MASCHMEYER G; GRUNEISEN A; EIMERMACHER H; SCHADECKGRESSEL C; HIDDEMANN W; BUCHNER T
      PROGNOSIS OF ELDERLY AML PATIENTS EXCLUDED FROM A RANDOMIZED MULTICENTER TRIAL

      Blood
    22. BUSKE C; UNTERHALT M; HERMANN R; KOCH P; TRUMPER L; BODENSTEIN H; DIETZFELBINGER H; LANDYS K; REUSS M; VETTER H; MASCHMEYER G; FREUND M; NEUBAUER A; ENGERT A; STAUDER R; HEROLD M; TIEMANN A; PAWARESCH R; STEIN H; HIDDEMANN W
      TREATMENT OF LOW-GRADE B-NHL WITH PREDNIMUSTINE IS NOT ASSOCIATED WITH AN INCREASED RISK FOR SECONDARY, NEOPLASIA

      Blood
    23. UNTERHALT M; HERMANN R; KOCH P; TRUMPER L; BODENSTEIN H; DIETZFELBINGER H; LANDYS K; REUSS M; VETTER H; MASCHMEYER G; FREUND M; NEUBAUER A; ENGERT A; STAUDER R; HEROLD M; TIEMANN M; PARWARESCH R; STEIN H; HIDDEMANN W
      PROGNOSTIC DETERMINANTS FOR LONG-TERM OUTCOME OF LOW-GRADE FOLLICULARLYMPHOMAS AFTER CYTOREDUCTIVE CHEMOTHERAPY AND INTERFERON-ALPHA MAINTENANCE - RESULTS OF THE GERMAN LOW-GRADE LYMPHOMA STUDY-GROUP (GLSG)

      Blood
    24. BUCHNER T; HIDDEMANN W; WORMANN B; LOFFLER H; GASSMANN W; HAFERLACH T; FONATSCH C; HOSSFELD D; MASCHMEYER G; LENGFELDER E; AUL C; HEYLL A; LUDWIG WD; SAUERLAND MC; HEINECKE A
      LATE EVENTS IN AML - DATA FROM LONG-TERM OBSERVATION OF PATIENTS IN 2TRIALS STARTING IN 1981 AND 1985

      Blood
    25. BUCHNER T; HIDDEMANN W; WORMANN B; LOFFLER H; GASSMANN W; HAFERLACH T; FONATSCH C; HOSSFELD D; MASCHMEYER G; LENGFELDER E; AUL C; HEYLL A; LUDWIG WD; SAUERLAND MC; HEINECKE A
      THERAPEUTIC OUTCOME IN AML IS MAINLY DETERMINED BY CYTOGENETICS, LDH IN SERUM, EARLY RESPONSE AND, IN A POOR-RISK SUBGROUP, BY INTENSIFIED INDUCTION TREATMENT

      Blood
    26. BUCHNER T; HIDDEMANN W; WORMANN B; LOFFLER H; GASSMANN W; HAFERLACH T; FONATSCH C; HOSSFELD D; LENGFELDER E; LUDWIG WD; MASCHMEYER G; SAUERLAND MC; HEINECKE A
      DAUNORUBICIN 60 INSTEAD OF 30 MG SQM IMPROVES RESPONSE AND SURVIVAL IN ELDERLY PATIENTS WITH AML/

      Blood
    27. MASCHMEYER G; VOGT K; HAHN H; DORKEN B
      ANTIMICROBIAL TREATMENT IN THE PRESENCE O F NEUTROPENIA

      Deutsche Medizinische Wochenschrift
    28. HIDDEMANN W; MASCHMEYER G; RUNDE V; EINSELE H
      PREVENTION, DIAGNOSIS AND TREATMENT OF IN FECTIONS IN PATIENTS WITH MALIGNANT DISEASES

      Der Internist
    29. HOELZER D; GOKBUGET N; ARNOLD R; BUCHNER T; FREUND M; GASSMANN W; HEIL G; HIDDEMANN W; LOFFLER H; LIPP T; LUDWIG WD; MASCHMEYER G; THIEL E; MESSERER D
      ACUTE LYMPHATIC-LEUKEMIA IN THE ADULT - D IAGNOSIS, RISK GROUPS AND TREATMENT

      Der Internist
    30. BUCHNER T; HIDDEMANN W; WORMANN B; LOFFLER H; GASSMANN W; HAFERLACH T; HEYLL A; AUL T; LENGFELDER E; MASCHMEYER G; LUDWIG WD; SAUERLAND MC; HEINECKE A
      INTENSIVE CONSOLIDATION VERSUS PROLONGED MAINTENANCE FOLLOWING INTENSIVE INDUCTION AND CONVENTIONAL CONSOLIDATION IN PRIMARY AML - A STUDY BY AMLCG

      Blood
    31. UNTERHALT M; HERMANN R; KOCH P; TRUMPER L; BODENSTEIN H; DIETZFELBINGER H; LANDYS K; REUSS M; VETTER H; MASCHMEYER G; FREUND M; NEUBAUER A; ENGERT A; STAUDER R; HEROLD M; TIEMANN M; PARWARESCH R; STEIN H; HIDDEMANN W
      LONG-TERM INTERFERON-ALPHA MAINTENANCE PROLONGS REMISSION DURATION INADVANCED LOW-GRADE LYMPHOMAS AND IS RELATED TO THE EFFICACY OF INITIAL CYTOREDUCTIVE CHEMOTHERAPY

      Blood
    32. HOELZER D; LUDWIG WD; THIEL E; GASSMANN W; LOFFLER H; FONATSCH C; RIEDER H; HEIL G; HEINZE B; ARNOLD R; HOSSFELD D; BUCHNER T; KOCH P; FREUND M; HIDDEMANN W; MASCHMEYER G; HEYLL A; AUL C; FAAK T; KUSE R; ITTEL TH; GRAMATZKI M; DIEDRICH H; KOLBE K; FUHR HG; FISCHER K; SCHADECKGRESSEL C; WEISS A; STROHSCHEER I; METZNER B; FABRY U; GOKBUGET N; VOLKERS B; MESSERER D; UBERLA K
      IMPROVED OUTCOME IN ADULT B-CELL ACUTE LYMPHOBLASTIC-LEUKEMIA

      Blood
    33. SPERLING C; BUCHNER T; CREUTZIG U; RITTER J; HARBOTT J; FONATSCH C; SAUERLAND C; MIELCAREK M; MASCHMEYER G; LOFFLER H; LUDWIG WD
      CLINICAL, MORPHOLOGIC, CYTOGENETIC AND PROGNOSTIC IMPLICATIONS OF CD34 EXPRESSION IN CHILDHOOD AND ADULT DE-NOVO AML

      Leukemia & lymphoma
    34. BUCHNER T; HIDDEMANN W; LOFFLER H; FONATSCH C; GASSMANN W; MASCHMEYER G; LUDWIG WD; HEYLL A; HOSSFELD D; SAUERLAND MC; HEINECKE A
      TREATMENT OF AML IN THE ELDERLY - FULL-DOSE VERSUS REDUCED DOSE INDUCTION TREATMENT

      Blood
    35. UNTERHALT M; HERRMANN R; NAHLER M; TRUMPER L; BODENSTEIN H; LANDYS K; REUSS M; VETTER H; MASCHMEYER G; FREUND M; NEUBAUER A; ENGERT A; STAUDER R; TIEMANN M; PARWARESCH R; STEIN H; HIDDEMANN W
      SIGNIFICANT PROLONGATION OF DISEASE-FREE SURVIVAL IN ADVANCED LOW-GRADE NON-HODGKIN LYMPHOMAS (NHL) BY INTERFERON-ALPHA MAINTENANCE

      Blood
    36. SCHLEGELBERGER B; WEBERMATTHIESEN K; STERRY W; BARTELS H; SONNEN R; MASCHMEYER G; FELLER AC; GROTE W
      COMBINED IMMUNOPHENOTYPING AND KARYOTYPING IN PERIPHERAL T-CELL LYMPHOMAS DEMONSTRATING DIFFERENT CLONAL AND NONCLONAL CHROMOSOME-ABERRATIONS IN T-HELPER CELLS

      Leukemia & lymphoma
    37. LINK H; MASCHMEYER G; MEYER P; HIDDEMANN W; STILLE W; HELMERKING M; ADAM D
      INTERVENTIONAL ANTIMICROBIAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS

      Annals of hematology
    38. MASCHMEYER G; LINK H; HIDDEMANN W; MEYER P; HELMERKING M; EISENMANN E; SCHMITT J; ADAM D
      EMPIRICAL ANTIMICROBIAL TREATMENT OF NEUT ROPENIC PATIENTS - RESULTS OF A MULTICENTER TRIAL OF THE PAUL-EHRLICH-SOCIETY STUDY-GROUP ON INFECTIONS IN HEMATOLOGY

      Medizinische Klinik
    39. ROTTMANN R; BUCHNER T; HIDDEMANN W; WORMANN B; MASCHMEYER G; LUDWIG WD; ZUHLSDORF M
      GM-CSF MULTIPLE COURSE PRIMING AND LONG-TERM ADMINISTRATION IN NEWLY-DIAGNOSED ACUTE MYELOID-LEUKEMIA - COMPARISON OF 3 DIFFERENT GM-CSF ROUTES AND SCHEDULES WITH NO GM-CSF

      Onkologie
    40. MASCHMEYER G; BUCHNER T; HIDDEMANN W; GASSMANN W; HEINECKE A; SAUERLAND MC; LOFFLER H; HEIT W
      A NOVEL REGIMEN FOR CONSOLIDATION CHEMOTHERAPY IN ADULT ACUTE MYELOID-LEUKEMIA IN FIRST REMISSION

      Onkologie
    41. MASCHMEYER G; LINK H; HIDDEMANN W; MEYER P; HELMERKING M; EISENMANN E; SCHMITT J; ADAM D
      PULMONARY INFILTRATIONS IN FEBRILE PATIENTS WITH NEUTROPENIA - RISK-FACTORS AND OUTCOME UNDER EMPIRICAL ANTIMICROBIAL THERAPY IN A RANDOMIZED MULTICENTER STUDY

      Cancer
    42. BUCHNER T; HIDDEMANN W; WORMANN B; ROTTMANN R; ZUHLSDORF M; MASCHMEYER G; LUDWIG WD; SAUERLAND MC; FRISCH J; SCHULZ G
      GM-CSF MULTIPLE COURSE PRIMING AND LONG-TERM ADMINISTRATION IN NEWLY-DIAGNOSED AML HEMATOLOGIC AND THERAPEUTIC EFFECTS

      Blood
    43. UNTERHALT M; KOCH P; PFREUNDSCHUH M; MASCHMEYER G; FREUND M; THIEL E; NEUBAUER A; DIETZFELBINGER R; ENGERT A; STAUDER M; HERRMANN R; TIEMANN M; PARWARESCH R; HIDDEMANN W
      PREDNIMUSTINE, MITOXANTRONE (PMM) VERSUS CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISONE (COP) FOR THE TREATMENT OF ADVANCED LOW-GRADE NON-HODGKIN-LYMPHOMA

      Blood
    44. BUCHNER T; HIDDEMANN W; LOFFLER H; GASSMANN W; MASCHMEYER G; LUDWIG WD; AUL C; LENGFELDER E; BOECKMANN A; SAUERLAND MC; HEINECKE A
      DOUBLE INDUCTION STRATEGY IN AML COMPARING HIGH WITH STANDARD-DOSE ARA-C - HEMATOTOXICITY AND ANTILEUKEMIC EFFICACY

      Blood
    45. HAFERLACH T; LOFFLER H; GASSMANN W; BENNETT JM; LUDWIG WD; MASCHMEYER G; THIEL E; NOWROUSIAN MR; LANG R; KUBICA U; WEISS A; LENGFELDER E; KOCH P; WEH HJ; TIRIER C; SAUERLAND MC; HEINECKE A; BUCHNER T
      CYTOMORPHOLOGICAL FEATURES AND PROGNOSTIC FACTORS IN 33 PATIENTS WITHACUTE MYELOID-LEUKEMIA (AML) AND TRANSLOCATION (8 21)

      Blood
    46. HIDDEMANN W; UNTERHALT M; THIEMANN M; PARWARESCH R; STEIN H; KOCH P; HERRMANN R; PFREUNDSCHUH M; MASCHMEYER G; FREUND M; THIEL E; NEUBAUER A; DIETZFELBINGER R; ENGERT A; STAUDER M
      CHARACTERISTICS AND CLINICAL COURSE OF FOLLICLE CENTER LYMPHOMAS AND MANTLE CELL LYMPHOMAS - A STUDY ON THE CLINICAL RELEVANCE OF THE R-E-A-L CLASSIFICATION

      Blood
    47. BUCHNER T; HIDDEMANN W; WORMANN B; ROTTMANN R; MASCHMEYER G; LUDWIG WD; ZUHLSDORF M; BUNTKIRCHEN K; SANDER A; ASWALD J; BINDER I; PRISETT S; SAUERLAND MC
      THE ROLE OF GM-CSF IN THE TREATMENT OF ACUTE MYELOID-LEUKEMIA

      Leukemia & lymphoma
    48. HAFERLACH T; GASSMANN W; LOFFLER H; JURGENSEN C; NOAK J; LUDWIG WD; THIEL E; HAASE D; FONATSCH C; BECHER R; SCHLEGELBERGER B; NOWROUSIAN MR; LENGFELDER E; EIMERMACHER H; WEH HJ; BRAUMANN D; MASCHMEYER G; KOCH P; HEINECKE A; SAUERLAND MC; BUCHNER T
      CLINICAL ASPECTS OF ACUTE MYELOID LEUKEMIAS OF THE FAB TYPE-M3 AND TYPE-M4EO

      Annals of hematology
    49. HOELZER D; THIEL E; LUDWIG WD; LOFFLER H; BUCHNER T; FREUND M; HEIL G; HIDDEMANN W; MASCHMEYER G; VOLKERS B; GOKBUGET N; AYDEMIR U
      FOLLOW-UP OF THE 1ST 2 SUCCESSIVE GERMAN MULTICENTER TRIALS FOR ADULTALL (01 81 AND 02/84)/

      Leukemia
    50. HOELZER D; ARNOLD R; AYDEMIR U; BUCHNER T; FREUND M; GASSMANN W; GOKBUGET N; HIDDEMANN W; KOCH P; LOFFLER H; LUDWIG WD; MASCHMEYER G; THIEL E; VOLKERS B
      RESULTS OF INTENSIFIED CONSOLIDATION THERAPY IN 4 CONSECUTIVE GERMAN MULTICENTER STUDIES FOR ADULT ALL

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 07:12:02